MannKind Projects $1 Billion in Revenue from United Therapeutics Deal and Targets Q4 Profitability
MannKind (MNKD) management has signaled a strategic shift from delivering developmental catalysts to executing on commercial milestones. The company anticipates achieving record revenue in the fourth quarter, which is expected to drive the firm toward profitability. A significant long-term growth driver identified is the partnership with United Therapeutics, which is projected to contribute approximately $1 billion in revenue between 2027 and 2030. This outlook reflects management's confidence in their ability to scale operations and monetize key assets over the coming years.
